News
Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback